- Home
- BEAG vs CERS Comparison
BEAG vs CERS Comparison
Compare BEAG & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAG
- CERS
- Stock Information
- Founded
- BEAG 2021
- CERS 1991
- Country
- BEAG United States
- CERS United States
- Employees
- BEAG N/A
- CERS N/A
- Industry
- BEAG
- CERS EDP Services
- Sector
- BEAG
- CERS Technology
- Exchange
- BEAG NYSE
- CERS Nasdaq
- Market Cap
- BEAG 317.4M
- CERS 347.3M
- IPO Year
- BEAG 2024
- CERS 1997
- Fundamental
- Price
- BEAG $10.49
- CERS $1.33
- Analyst Decision
- BEAG
- CERS Strong Buy
- Analyst Count
- BEAG 0
- CERS 2
- Target Price
- BEAG N/A
- CERS $3.50
- AVG Volume (30 Days)
- BEAG 171.0K
- CERS 1.0M
- Earning Date
- BEAG 01-01-0001
- CERS 05-01-2025
- Dividend Yield
- BEAG N/A
- CERS N/A
- EPS Growth
- BEAG 144.20
- CERS N/A
- EPS
- BEAG 0.21
- CERS N/A
- Revenue
- BEAG N/A
- CERS $185,144,000.00
- Revenue This Year
- BEAG N/A
- CERS $25.57
- Revenue Next Year
- BEAG N/A
- CERS $10.54
- P/E Ratio
- BEAG $50.00
- CERS N/A
- Revenue Growth
- BEAG N/A
- CERS 13.06
- 52 Week Low
- BEAG $9.84
- CERS $1.12
- 52 Week High
- BEAG $11.20
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- BEAG N/A
- CERS 50.29
- Support Level
- BEAG N/A
- CERS $1.28
- Resistance Level
- BEAG N/A
- CERS $1.38
- Average True Range (ATR)
- BEAG 0.00
- CERS 0.06
- MACD
- BEAG 0.00
- CERS 0.01
- Stochastic Oscillator
- BEAG 0.00
- CERS 65.00
About BEAG BOLD EAGLE ACQUISITION CORP
Bold Eagle Acquisition Corp is a blank check company.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.